Gastroenterology Report最新文献

{"title":"Protrusion of nasobiliary drainage catheter through the anus.","authors":"Dongrui Li, Yuanbo Bi, Shengxiong Chen, Tengfei Zhang, Yunfei Liang, Jiansheng Zhang","doi":"10.1093/gastro/goag086","DOIUrl":"10.1093/gastro/goag086","url":null,"abstract":"","PeriodicalId":54275,"journal":{"name":"Gastroenterology Report","volume":"14 ","pages":"goag086"},"PeriodicalIF":4.0,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13552377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148914339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world management of SeHCAT-confirmed bile acid diarrhoea: response to colestyramine and predictors of treatment success.","authors":"Eduard Brunet-Mas, Andrea Peña-Rosado, Belen Garcia-Sagué, Luis Enrique Frisancho, Luigi Melcarne, Laura Patricia Llovet, Anna Puy, Maria José Ramírez-Lázaro, Antonio Rodriguez Revuelto, Alberto Villoria, Xavier Calvet, Sergio Lario","doi":"10.1093/gastro/goag090","DOIUrl":"10.1093/gastro/goag090","url":null,"abstract":"<p><strong>Background: </strong>Bile acid diarrhoea (BAD) is an increasingly recognized cause of chronic diarrhoea. The 75-selenium homocholic acid taurine (SeHCAT) test remains the gold standard for diagnosis. The primary pharmacological treatment involves bile acid-binding agents, most commonly colestyramine. This study aimed to review the management of BAD at our centre and to identify factors associated with response to colestyramine.</p><p><strong>Materials and methods: </strong>This single-centre retrospective study included all patients with an abnormal SeHCAT test (retention <15%) from 1 January 2020 to 31 December 2023 associated with chronic diarrhoea. Patients receiving empiric bile acid chelators without prior SeHCAT testing and those under 18 years of age were excluded. The primary endpoint was treatment success with colestyramine, defined as complete or partial clinical response without treatment discontinuation due to intolerance. Univariable comparisons and multivariable logistic regression were performed to identify factors independently associated with treatment success.</p><p><strong>Results: </strong>Ninety-seven patients were included; 72.2% were women, with a mean age of 54.4 ± 15.1 years. Severe BAD was observed in 60.8% of cases. Overall, 77.3% of patients responded to colestyramine (43.2% complete, 34.0% partial). In multivariable analysis, baseline higher number of bowel movements per day was independently associated with a lower probability of treatment success (odds ratio 0.79, 95% confidence interval 0.68-0.92; <i>P </i>= 0.003). Colestyramine failure was generally due to intolerance-related discontinuation (17.5% of the cohort) followed by lack of efficacy (5.1%). No severe adverse events were documented.</p><p><strong>Conclusion: </strong>Colestyramine appears to be an effective first-line therapy for BAD in routine clinical practice. However, treatment success in this study reflects both clinical response and tolerability, as treatment failure was more frequently related to intolerance than lack of efficacy.</p>","PeriodicalId":54275,"journal":{"name":"Gastroenterology Report","volume":"14 ","pages":"goag090"},"PeriodicalIF":4.0,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13541380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148892818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Submucosal tunneling endoscopic resection combined with sequential traction for a large duodenal bulb adenoma.","authors":"Yue Zhu, Qianqian Wang, Yuxuan Chen, Mi Zhou, Jian Dai, Shuo Zhang","doi":"10.1093/gastro/goag091","DOIUrl":"10.1093/gastro/goag091","url":null,"abstract":"","PeriodicalId":54275,"journal":{"name":"Gastroenterology Report","volume":"14 ","pages":"goag091"},"PeriodicalIF":4.0,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13537317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148881768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A device for difficult oronasal exchange of nasobiliary catheter.","authors":"Xiaoqing Zhang, Mingwen Guo","doi":"10.1093/gastro/goag089","DOIUrl":"https://doi.org/10.1093/gastro/goag089","url":null,"abstract":"","PeriodicalId":54275,"journal":{"name":"Gastroenterology Report","volume":"14 ","pages":"goag089"},"PeriodicalIF":4.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a Bayesian network-based surgical risk-prediction tool for patients with small-bowel stricturing Crohn's disease.","authors":"Weijie Chen, Chuanding Li, Mengfan Chen, Chunhui Ouyang, Chunyan Peng, Xiaoqi Zhang, Zhiqiang Cai, Meiying Zeng, Xiaolei Wang","doi":"10.1093/gastro/goag083","DOIUrl":"https://doi.org/10.1093/gastro/goag083","url":null,"abstract":"<p><strong>Background: </strong>Patients with small-bowel stricturing Crohn's disease (sbsCD) usually have a higher risk of intestinal surgical resection. We aimed to develop a machine-learning model for predicting the 1-year surgery risk in these patients.</p><p><strong>Methods: </strong>This study included 520 retrospectively enrolled patients with sbsCD (training cohort, <i>n</i> = 416; testing cohort, <i>n</i> = 104) from January 2018 to May 2021 and 126 prospectively enrolled patients in the validation cohort from July 2021 to December 2023 across four centers for inflammatory bowel disease in China. Clinical and radiological features were assessed by using logistic regression analyses to identify independent surgery risk factors. Six predictive machine-learning models for 1-year surgical risk were developed and the model performance was comprehensively evaluated by constructing receiver-operating characteristic (ROC) curves and comparing area under the curve (AUC) values. Four simplified Bayesian network (BN)-based risk matrices were constructed for clinical practice.</p><p><strong>Results: </strong>There were 158 (24.4%) Crohn's disease (CD)-related surgeries during the 1-year follow-up. Eight selected predictors of surgery included penetrating lesions, nonuse of biologics, nonuse of corticosteroids, a CD obstructive score of ≥3, endoscopic strictures, anemia, radiologic luminal narrowing, and prestenotic dilation. Among the six models evaluated, the Tree-Augmented Naïve Bayes (TAN) model demonstrated optimal performance, with a mean AUC of 0.878. A further prospective validation cohort verified the efficacy of the model, with 87.5% specificity, 76.7% sensitivity, and 84.9% accuracy for predicting 1-year surgery. Four simplified BN-based risk matrices were constructed for practical use. An online prediction tool is available at http://prebn.site/.</p><p><strong>Conclusion: </strong>We developed and validated a TAN-based BN model incorporating clinical and radiological features to accurately predict the 1-year surgical risk for clinical application in patients with sbsCD, thereby providing a promising tool for decision-making.</p>","PeriodicalId":54275,"journal":{"name":"Gastroenterology Report","volume":"14 ","pages":"goag083"},"PeriodicalIF":4.0,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13480436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustained drug-free remission of refractory ulcerative colitis following rituximab therapy for Epstein-Barr virus-positive mucocutaneous ulcer.","authors":"Mohammed Nabil Quraishi, Najla Ben Ghashir, Kayane Mheidly","doi":"10.1093/gastro/goag088","DOIUrl":"https://doi.org/10.1093/gastro/goag088","url":null,"abstract":"","PeriodicalId":54275,"journal":{"name":"Gastroenterology Report","volume":"14 ","pages":"goag088"},"PeriodicalIF":4.0,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13472689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148763410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Celecoxib suppresses colorectal cancer growth by inhibiting propionyl-CoA carboxylase alpha chain-mediated epithelial-mesenchymal transition and angiogenesis.","authors":"Chuyi Zhang, Jielin Zheng, Yingyin Zhao, Fai Leong, Jiahe Xu, Zhunyi Gao, Ziwei Qi, Yuhui Huang, Sanqing Jin","doi":"10.1093/gastro/goag071","DOIUrl":"10.1093/gastro/goag071","url":null,"abstract":"<p><strong>Background: </strong>Celecoxib is widely used in the prevention and treatment of colorectal cancer (CRC). Although its mechanism of action involves both cyclooxygenase-2 (COX-2)-dependent and COX-2-independent pathways, the non-COX-2 targets of celecoxib remain poorly understood. Preliminary experiments revealed that celecoxib can inhibit the expression of the propionyl-CoA carboxylase alpha chain (PCCA); hence, this study aimed to investigate the role and underlying mechanisms of PCCA as a non-COX-2 target of celecoxib.</p><p><strong>Methods: </strong>Wound-healing, transwell, and Cell Counting Kit-8 assays were conducted to evaluate the effects of celecoxib on migration, invasion, and proliferation in PCCA-overexpressing CRC cell lines. Western blotting was performed to assess the expression of epithelial-mesenchymal transition (EMT) markers. <i>In vivo</i> tumor growth and angiogenesis were examined by using mouse models. Quantitative polymerase chain reaction was used to analyse the transcriptional levels of placental growth factor (<i>PLGF</i>).</p><p><strong>Results: </strong>Celecoxib inhibited PCCA expression in CRC and suppressed PCCA-mediated migration, invasion, and proliferation in COX-2-deficient CRC cell lines (HCT116 and DLD1). These effects were associated with the reversal of PCCA-induced downregulation of E-cadherin and upregulation of N-cadherin and vimentin. In addition, celecoxib inhibited PCCA-driven tumor growth and angiogenesis in HCT116 cells, which correlated with altered <i>PLGF</i> expression.</p><p><strong>Conclusion: </strong>Celecoxib suppresses PCCA-induced EMT and angiogenesis via a COX-2-independent mechanism. These findings suggest that celecoxib may offer additional therapeutic benefits for patients with CRC with elevated PCCA expression and reveal a novel potential antitumor mechanism of celecoxib.</p>","PeriodicalId":54275,"journal":{"name":"Gastroenterology Report","volume":"14 ","pages":"goag071"},"PeriodicalIF":4.0,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148714433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of homozygous germline mutation at the MLH3 splicing site causing infertility, colon polyposis with synchronous multiple colon cancers, and osteoma.","authors":"Jiabo Gu, Jun Wang, Defu Zhou, Heiying Jin","doi":"10.1093/gastro/goag082","DOIUrl":"10.1093/gastro/goag082","url":null,"abstract":"","PeriodicalId":54275,"journal":{"name":"Gastroenterology Report","volume":"14 ","pages":"goag082"},"PeriodicalIF":4.0,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13450683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148698130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between preoperative pan-esophageal pressurization and peristalsis recovery after per-oral endoscopic myotomy in achalasia.","authors":"Dianxuan Jiang, Ruoxi Zhang, Peiwen Dong, Shimin Chen, Wei Zhao, Songfeng Chen, Niandi Tan, Mengyu Zhang, Qianjun Zhuang, Xiaoqing Li, Qiong Wang, Nina Zhang, Yinglian Xiao","doi":"10.1093/gastro/goag081","DOIUrl":"10.1093/gastro/goag081","url":null,"abstract":"<p><strong>Background: </strong>Per-oral endoscopic myotomy (POEM) has become the mainstream treatment for achalasia. Previous studies have found that some patients with achalasia might experience partial recovery of esophageal peristalsis after POEM. However, the clinical significance of this recovery and the associated factors remain to be further elucidated.</p><p><strong>Methods: </strong>This was a multicenter retrospective cohort study conducted by four academic hospitals in China. Patients diagnosed with achalasia who underwent POEM between 2020 and 2025 were included. Demographics, Eckardt score, gastroesophageal reflux disease questionnaire (GERDQ) score, presence of esophagitis, high-resolution manometry parameters, and myotomy length were collected. Normal, weak, and fragmented contractions were defined as partial recovery of esophageal peristalsis.</p><p><strong>Results: </strong>Partial recovery of esophageal peristalsis was observed in 32.8% (95 of 290) of patients with achalasia. A significantly higher preoperative proportion of pan-esophageal pressurization was found in the recovery group compared with the non-recovery group [median (interquartile range), 80.0% (30.0%, 100.0%) vs 30.0% (0.0%, 90.0%), <i>P </i>< 0.001] and this proportion positively correlated with the degree of peristalsis recovery (<i>r</i> = 0.247, <i>P </i>< 0.001). Patients with peristalsis recovery had significantly lower GERDQ scores and reduced incidence of dysphagia symptoms. Multivariate analysis further confirmed that the preoperative proportion of pan-esophageal pressurization was an independent predictor of peristalsis recovery (odds ratio = 1.02, <i>P </i>= 0.007).</p><p><strong>Conclusions: </strong>A higher preoperative proportion of pan-esophageal pressurization was independently associated with postoperative recovery of esophageal peristalsis in patients with achalasia. Peristalsis recovery was related to superior symptom relief. Preoperative assessment of pan-esophageal pressurization might help guide individualized postoperative follow-up and patient counseling.</p>","PeriodicalId":54275,"journal":{"name":"Gastroenterology Report","volume":"14 ","pages":"goag081"},"PeriodicalIF":4.0,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13435606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148674433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor-microenvironment-mediated immune escape drives trastuzumab resistance in HER2-positive gastric cancer.","authors":"Huifang Lv, Wanying Zhao, Sai-Qi Wang, Yunduan He, Caiyun Nie, Xiao-Bing Chen","doi":"10.1093/gastro/goag068","DOIUrl":"10.1093/gastro/goag068","url":null,"abstract":"<p><p>The combination of trastuzumab and chemotherapy, with or without pembrolizumab, is the current first-line standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer and gastroesophageal junction cancer. However, upon disease progression, subsequent therapies often yield limited clinical benefit. The mechanisms of drug resistance to trastuzumab remain unresolved. Current studies on its resistance mechanisms have largely focused on alterations in the HER2 pathway, including HER2 heterogeneity, reduced or absent HER2 expression, variations in HER2 dimerization, and mutations in downstream components, among others. Crucially, as a monoclonal antibody, the antitumor activity of trastuzumab is partially mediated by the immune system, yet the immunology-related mechanisms of resistance are frequently overlooked. In this review, we systematically analyse the outcomes of both successful and failed clinical trials of anti-HER2 agents to propose that immune escape within the tumor microenvironment is a key driver of trastuzumab resistance in HER2-positive gastric cancer.</p>","PeriodicalId":54275,"journal":{"name":"Gastroenterology Report","volume":"14 ","pages":"goag068"},"PeriodicalIF":4.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13427768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148654300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}